← All trials
NCT00115895
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2000
- Primary completion
- Oct 31, 2004
- Completion date
- Sep 30, 2020
- First posted
- Jun 27, 2005
- Last posted
- Mar 2, 2018
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of HelsinkiLead sponsor
- University of HelsinkiCollaborator
- University of HelsinkiReponsible party - principal investigator
- University of HelsinkiSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.